The second case involved a kidney angiomyolipoma in a 45-year-old male with RRMS after 6 months of interferon beta therapy, followed by 7 months of ocrelizumab therapy (after induction and one dose of management). This evidence concerns the gene IFNB1 and kidney angiomyolipoma.